Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES PLATZER IN CONNECTION WITH ITS LISTING ON NASDAQ OMX STOCKHOLM AND NEW ISSUE OF SHARES
Mandate

VINGE ADVISES PLATZER IN CONNECTION WITH ITS LISTING ON NASDAQ OMX STOCKHOLM AND NEW ISSUE OF SHARES

November 28, 2013

Vinge is advising Platzer Fastigheter Holding AB in connection with the listing of Platzer’s shares on NASDAQ OMX Stockholm. In connection with the listing, a new issue of class B shares will be performed which is intended to be directed to both the general public and institutional investors and is expected to generate capital for Platzer in the region of SEK 632-708 million.

Vinge’s team primarily consists of responsible partner Olof Jisland, partners Anders Strid (capital markets) and Ulf Käll, and associates Anna Hofling Johansson (tax) as well as Ingrid Johansson and Emma Kero Ljungberg (due diligence and prospectus).

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026